within Pharmacolibrary.Drugs.ATC.N;

model N02CD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00151,
    adminDuration  = 600,
    adminMass      = 0.225,
    adminCount     = 1,
    Vd             = 0.0039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fremanezumab is a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), used to prevent migraine attacks in adults. It is approved and currently used as a preventive therapy for migraine, reducing headache frequency and severity.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model reported for adult patients (including healthy subjects and migraine patients) aged 18–70 years. Parameters represent results after subcutaneous administration.</p><h4>References</h4><ol><li><p>Lionetto, L, et al., &amp; Martelletti, P (2019). Fremanezumab for the prevention of chronic and episodic migraine. <i>Drugs of today (Barcelona, Spain : 1998)</i> 55(4) 265–276. DOI:<a href=&quot;https://doi.org/10.1358/dot.2019.55.4.2970909&quot;>10.1358/dot.2019.55.4.2970909</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31050694/&quot;>https://pubmed.ncbi.nlm.nih.gov/31050694</a></p></li><li><p>Fiedler-Kelly, JB, et al., &amp; Levi, M (2019). Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. <i>British journal of clinical pharmacology</i> 85(12) 2721–2733. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14096&quot;>10.1111/bcp.14096</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31418911/&quot;>https://pubmed.ncbi.nlm.nih.gov/31418911</a></p></li><li><p>Cohen-Barak, O, et al., &amp; Aycardi, E (2018). A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. <i>Cephalalgia : an international journal of headache</i> 38(13) 1960–1971. DOI:<a href=&quot;https://doi.org/10.1177/0333102418771376&quot;>10.1177/0333102418771376</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29667896/&quot;>https://pubmed.ncbi.nlm.nih.gov/29667896</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CD03;
